secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2025-03-12T23:59:59+00:00
Accession:  0000950170-25-037634
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa to pursue metastatic breast cancer indication; (Z)-endoxifen more than doubled PFS vs tamoxifen (7.2 vs 2.4 mo)
--------------------------------------------------------------------------------

- Strategic decision to pursue metastatic breast cancer indication for (Z)-endoxifen, citing potentially faster regulatory path.
- Median PFS more than doubled to 7.2 months vs 2.4 months for tamoxifen in CDK4/6i-naïve patients.
- Also engaging FDA on additional indications: breast cancer prevention and neoadjuvant therapy.
- Early data show Ki-67 ≤10% response rate above 85% across doses in neoadjuvant setting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000095017025037634/0000950170-25-037634-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000095017025037634/atos-20250311.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-037634

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer